Blastic plasmacytoid dendritic cell neoplasm

Clinical Advances in Hematology and Oncology

Volumn 14, Issue 4, 2016, Pages 220-222

  Pemmaraju, Naveen ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD123 ANTIGEN; CD4 ANTIGEN; CD56 ANTIGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; LORVOTUZUMAB MERTANSINE; PREDNISONE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM; FLOW CYTOMETRY; GENE MUTATION; GENE SEQUENCE; HODGKIN DISEASE; HUMAN; NEOPLASM; NOTE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; STEM CELL TRANSPLANTATION; T CELL LEUKEMIA; TUMOR VOLUME; DENDRITIC CELL; HEMATOLOGIC NEOPLASMS; INTERVIEW; MORTALITY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROGNOSIS; RARE DISEASE; RESEARCH; TREATMENT OUTCOME;

COMBINED MODALITY THERAPY; DENDRITIC CELLS; HEMATOLOGIC NEOPLASMS; HUMANS; PROGNOSIS; RARE DISEASES; RESEARCH; TREATMENT OUTCOME;

EID: 84964303658     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (13)

1. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114(5):937-951.
2. Pagano L, Valentini CG, Pulsoni A, et al; GIMEMA-ALWP (Gruppo Italiano Malattie EMatologiche dell’Adulto, Acute Leukemia Working Party). Blastic plas-macytoid dendritic cell neoplasm with leukemic presentation: an Italian multicenter study. Haematologica. 2013;98(2):239-246.
3. Taylor J, Kim SS, Stevenson KE, et al. Loss-of-function mutations in the splicing factor ZRSR2 are common in blastic plasmacytoid dendritic cell neoplasm and have male predominance [ASH abstract 741]. Blood. 2013;122(21)(suppl).
4. Pemmaraju N, Kantarjian HM, Cortes JE, et al. Blastic plasmacytoid dendritic cell neoplasm (BPDCN): a large single-center experience: analysis of clinical and molecular characteristics and patient outcomes [ASH abstract 3746]. Blood. 2015;126(23)(suppl).
5. Alayed K, Patel KP, Konoplev S, et al. TET2 mutations, myelodysplastic features, and a distinct immunoprofile characterize blastic plasmacytoid dendritic cell neoplasm in the bone marrow. Am J Hematol. 2013;88(12):1055-1061.
6. Roos-Weil D, Dietrich S, Boumendil A, et al; European Group for Blood and Marrow Transplantation Lymphoma, Pediatric Diseases, and Acute Leukemia Working Parties. Stem cell transplantation can provide durable disease control in blastic plasmacytoid dendritic cell neoplasm: a retrospective study from the European Group for Blood and Marrow Transplantation. Blood. 2013;121(3):440-446.
7. Aoki T, Suzuki R, Kuwatsuka Y, et al. Long-term survival following autologous and allogeneic stem cell transplantation for blastic plasmacytoid dendritic cell neoplasm. Blood. 2015;125(23):3559-3562.
8. FitzGerald DJ. Targeted diphtheria toxin to treat BPDCN. Blood. 2014;124(3):310-312.
9. Frankel AE, Woo JH, Ahn C, et al. Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients. Blood. 2014;124(3):385-392.
10. Sweet KL, Pemmaraju N, Lane AA, et al. Lead-in stage results of a pivotal trial of SL-401, an interleukin-3 receptor (IL-3R) targeting biologic, in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) or acute myeloid leukemia (AML) [ASH abstract 3795]. Blood. 2015;126(23)(suppl).
11. ClinicalTrials.gov. An open-label phase II study of lorvotuzumab mertansine. Identifier: NCT02420873. https://clinicaltrials.gov/ct2/show/NCT02420873. Updated September 3, 2015. Accessed March 7, 2016.
12. Jardin F, Ruminy P, Parmentier F, et al. TET2 and TP53 mutations are frequently observed in blastic plasmacytoid dendritic cell neoplasm. Br J Haematol. 2011;153(3):413-416.
13. Menezes J, Acquadro F, Wiseman M, et al. Exome sequencing reveals novel and recurrent mutations with clinical impact in blastic plasmacytoid dendritic cell neoplasm. Leukemia. 2014;28(4):823-829.